Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|BRCA-Associated Malignant Neoplasm|BRCA-Associated Ovarian Carcinoma|Metastatic BRCA-Associated Breast Carcinoma|Metastatic Breast Carcinoma|Metastatic Fallopian Tube Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Metastatic Pancreatic Carcinoma|Metastatic Primary Peritoneal Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Unresectable Breast Carcinoma|Unresectable Fallopian Tube Carcinoma|Unresectable Malignant Solid Neoplasm|Unresectable Ovarian Carcinoma|Unresectable Pancreatic Carcinoma|Unresectable Primary Peritoneal Carcinoma
Interventions: BIOLOGICAL: Dostarlimab|DRUG: Niraparib
Sponsor: University of Washington
Collaborators: GlaxoSmithKline